LABU240920C170000
- 0.24
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Gilead Sciences Unusual Options Activity For September 20
Viking, Structure, Terns Benefitting From Disappointing Novo Nordisk Weight Loss Data
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
Behind the Scenes of Amgen's Latest Options Trends
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
10 Health Care Stocks With Whale Alerts In Today's Session
28 Top Rated U.S. Growth Stocks Month-to-date in Anticipation of Fed Cuts
What the Options Market Tells Us About Viking Therapeutics
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Natera Shares Are Trading Higher After the Company Announced the Publication of Three Peer-reviewed Papers, Resulting in Over 85 Peer-reviewed Publications on Its Cancer Diagnostic Test Signatera
Exas Science Shares Are Trading Higher After the Company Announced Data for Its Blood-based Colorectal Cancer Screening Test.